MedTrace Logo

Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT01260324 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21283

Last updated 2021-02-01

Study results available
· View outcomes & findings →

Summary

The objectives of this study were to: (1) evaluate the natural history of non-arteritic anterior ischemic optic neuropathy (NAION); (2) estimate the population incidence of NAION; and (3) identify potential risk factors for NAION.

Conditions

  • Anterior Ischemic Optic Neuropathy
  • Ischemic Optic Neuropathy

Interventions

OTHER

No intervention given in this observational study

No intervention given in this observational study

OTHER

No intervention given in this observational study

No intervention given in this observational study

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-03-31
Completion
2010-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01260324 on ClinicalTrials.gov